Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Ono Gains Rights To Onyx Drugs In Japan
by Rick Mullin
September 13, 2010
| A version of this story appeared in
Volume 88, Issue 37
Onyx Pharmaceuticals and Japan’s Ono Pharmaceutical will collaborate on two of Onyx’ proteasome inhibitors. In exchange for development and commercialization rights in Japan, Ono will pay Onyx about $59 million up front; additional milestone payments could bring the deal’s value to more than $300 million. The compounds are carfilzomib, a highly selective proteasome inhibitor in clinical trials for multiple myeloma, and ONX 0912, a treatment for solid tumors. Onyx obtained carfilzomib with the acquisition of Proteolix last year (C&EN, Oct. 19, 2009, page 19).
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter